Markets

Insider Trading

Hedge Funds

Retirement

Opinion

11 Best CBD Stocks To Buy Now

In this article, we discuss 11 best CBD stocks to buy now. If you want to see more stocks in this selection, check out 5 Best CBD Stocks To Buy Now

The cannabis industry in 2022 had mixed results. While some new markets experienced significant growth, sales in many established markets decreased, slowing or even reversing growth in those areas. This can partly be attributed to the impact of COVID-19 on the wider economy, but it resulted in numerous companies facing challenges such as job cuts, financial difficulties, and increased debt.

However, 2022 had its positive aspects as well. Three more American states passed laws legalizing the use of cannabis for adults, and recreational sales were launched in other states. On a federal level, the Biden administration made progress towards reform by pardoning federal offenses for simple marijuana possession and directing a review of the classification of cannabis under federal law. Additionally, Congress passed the Medical Marijuana and Cannabidiol Research Expansion Act. At the same time, legal retailers continue to struggle with onerous taxes, regulations, and competition from the illegal market. Many of these same challenges are likely to persist throughout 2023, including the slump in wholesale and retail cannabis prices.

The growth rate of legal cannabis sales in the United States, which does not require federal legalization, is expected to increase at a rate with double-digit annual compound growth, said Cowen analyst Vivien Azer in a report on January 10. According to Rick Maturo, the Director of Insights and Intelligence for the cannabis data company BDSA, the pressure of lowering prices and competition from illegal sources will lead to a consolidation of the thousands of US cannabis brands. He also suggested that the sales projections for cannabis in New York may decrease due to the state’s difficulty in combating the illicit market and issues with establishing social equity licensees. At the same time, Maturo predicts an increase in the marketing of premium edible and concentrated products that are marketed as containing “solventless” cannabinoids.

Marijuana is rapidly gaining popularity in multiple states. A recent poll by the Hobby School of Public Affairs at the University of Houston shows that the majority of Texans support the legalization of medical marijuana. According to the poll results, 82% of Texans are in favor of the Legislature passing a bill that would allow people to use marijuana for medical purposes with a prescription. Additionally, 56% of those polled strongly support medical marijuana. The support was consistent across different demographics, with 85% of Latino Texans, 83% of Black Texans, 80% of white Texans, 83% of women, 80% of men, 93% of Democrats, 79% of independents, and 73% of Republicans all expressing approval. 

Some of the best marijuana stocks to consider include Jazz Pharmaceuticals plc (NASDAQ:JAZZ), The Scotts Miracle-Gro Company (NYSE:SMG), and Tilray Brands, Inc. (NASDAQ:TLRY). 

Our Methodology 

We selected the following marijuana stocks based on overall hedge fund sentiment toward each stock. We have assessed the hedge fund sentiment from Insider Monkey’s database of 920 elite hedge funds tracked as of the end of the third quarter of 2022. The list is arranged in ascending order of the number of hedge fund holders in each firm. 

Best CBD Stocks To Buy Now

11. GrowGeneration Corp. (NASDAQ:GRWG)

Number of Hedge Fund Holders: 5

GrowGeneration Corp. (NASDAQ:GRWG) was founded in 2008 and is based in Greenwood Village, Colorado. GrowGeneration Corp. (NASDAQ:GRWG) is involved in the hydroponic and organic gardening retail industry in the US. It sells and markets products such as nutrients, lighting, environmental control systems, and accessories for hydroponic gardening and other indoor and outdoor growing. Its target customers are commercial and urban cultivators who grow specialty crops like organic greens and plant-based medicines. In March 2021, GrowGeneration Corp. (NASDAQ:GRWG) acquired Aquarius Hydroponics, an indoor-outdoor garden supply center specializing in hydroponics systems, lighting, and nutrients, representing its entry into Massachusetts’ cannabis market. 

On November 16, GrowGeneration Corp. (NASDAQ:GRWG) formed a strategic partnership with Grodan, a leading producer of stone wool growing media solutions for hydroponics operations. The partnership between GrowGeneration and Grodan will strengthen GrowGen’s market position and expand the availability of Grodan products to more customers at competitive prices.

Alliance Global Partners analyst Aaron Grey on November 8 maintained a Neutral rating on GrowGeneration Corp. (NASDAQ:GRWG) and lowered the firm’s price target on the shares to C$4 from C$4.50 following the Q3 results. The analyst cited uncertainty about when the growth of the industry will return to a sustainable level due to the absence of promotional activity.

According to Insider Monkey’s data, 5 hedge funds were bullish on GrowGeneration Corp. (NASDAQ:GRWG) at the end of the third quarter of 2022, compared to 4 funds in the prior quarter. The collective stakes in Q3 2022 amounted to $7.3 million, up from $6.2 million in Q2. D E Shaw is the biggest stakeholder of the company, with 889,524 worth $3.1 million. 

Like Jazz Pharmaceuticals plc (NASDAQ:JAZZ), The Scotts Miracle-Gro Company (NYSE:SMG), and Tilray Brands, Inc. (NASDAQ:TLRY), GrowGeneration Corp. (NASDAQ:GRWG) is one of the best marijuana stocks to montior. 

10. Village Farms International, Inc. (NASDAQ:VFF)

Number of Hedge Fund Holders: 6

Village Farms International, Inc. (NASDAQ:VFF) was founded in 1989 and is headquartered in Delta, Canada. The company, along with its subsidiaries, grows, markets, and distributes greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. It operates through four business segments – Produce, Cannabis-Canada, Cannabis-U.S., and Energy. Village Farms International, Inc. (NASDAQ:VFF) is also involved in the production and distribution of cannabis products to licensed providers and government agencies in Canada and other countries. It develops and sells cannabinoid-based health and wellness products including ingestible, edibles, and topical products. It is one of the best marijuana stocks to invest in. 

On January 3, Village Farms International, Inc. (NASDAQ:VFF) announced the advancement of its international cannabis strategy by starting to ship cannabis products to Israel. Village Farms International, Inc. (NASDAQ:VFF) also disclosed that it is continuing to implement its global cannabis strategy, which includes increased sales in the Australian medical market and plans to enter the German medical market.

Alliance Global Partners analyst Aaron Grey on February 3 maintained a Buy recommendation on Village Farms International, Inc. (NASDAQ:VFF) but lowered the firm’s price target on the shares to $3 from $6. This change is due to the recent equity raise by the company and the anticipated trends for Q4. The analyst acknowledged the continued cash burn from produce but still views Village Farms International, Inc. (NASDAQ:VFF) as a stable player in the cannabis industry and has seen consistent share performance over the past two years among Canadian LPs.

According to Insider Monkey’s third quarter database, 6 hedge funds were bullish on Village Farms International, Inc. (NASDAQ:VFF), compared to 5 funds in the prior quarter. Jim Simons’ Renaissance Technologies is the biggest position holder in the company, with 249,661 shares worth $477,000. 

9. Clever Leaves Holdings Inc. (NASDAQ:CLVR)

Number of Hedge Fund Holders: 6

Clever Leaves Holdings Inc. (NASDAQ:CLVR) is a Florida-based cannabis company engaged in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment of the company is involved in the creation, production, promotion, sale, distribution, and commercialization of nutraceuticals and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements. It is one of the best marijuana stocks to monitor. 

On November 11, Canaccord analyst Bobby Burleson downgraded Clever Leaves Holdings Inc. (NASDAQ:CLVR) from Buy to Hold and lowered the price target on the shares to 80 cents from $3. He believes that Clever Leaves Holdings Inc. (NASDAQ:CLVR) has established a strong business to meet the demand for global cannabis, but he is being cautious about the timing of significant revenue growth. The trimmed price target is due to the lower earnings estimates and general reduction in valuations for the cannabis sector, according to the analyst.

According to Insider Monkey’s Q3 data, 6 hedge funds were long Clever Leaves Holdings Inc. (NASDAQ:CLVR), compared to 5 in the last quarter. Thomas Steyer’s Farallon Capital is the largest stakeholder of the company, with 2.46 million shares worth $1.48 million. 

8. Organigram Holdings Inc. (NASDAQ:OGI)

Number of Hedge Fund Holders: 7

Organigram Holdings Inc. (NASDAQ:OGI) was incorporated in 2010 and is headquartered in Toronto, Canada. The company engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, such as cannabis flowers, gummies, cannabis oils, vaporizers, cannabis edibles, and concentrates. Organigram Holdings Inc. (NASDAQ:OGI) is one of the premier marijuana stocks to consider. 

On January 12, Organigram Holdings Inc. (NASDAQ:OGI) reported a Q1 net income of $5.33 million, and revenue for the period climbed 42.4% year-over-year to $43.3 million, beating Wall Street estimates by $10.89 million. The company anticipates that its revenue for FQ2 2023 will be higher than its revenue for FQ2 2022. 

Stifel analyst Andrew Partheniou upgraded Organigram Holdings Inc. (NASDAQ:OGI) on January 13 to Buy from Hold with an unchanged price target of C$1.50, due to the company’s strong Q1 results, which showed profitability that exceeded expectations and significant cash generation. The analyst has also raised his profitability estimates to reflect the Q1 performance, the company’s production expansions and innovative efforts, and management’s gross margin guidance.

According to Insider Monkey’s third quarter database, Organigram Holdings Inc. (NASDAQ:OGI) was part of 7 hedge fund portfolios, with collective stakes worth $3.7 million. D E Shaw held the largest stake in the company, with 2.4 million shares worth $2.15 million. 

7. Cronos Group Inc. (NASDAQ:CRON)

Number of Hedge Fund Holders: 8

Cronos Group Inc. (NASDAQ:CRON) was founded in 2012 and is based in Toronto, Canada. Cronos Group Inc. (NASDAQ:CRON) is a cannabinoid company that operates in the hemp-based supplement and cosmetic product market. The company sells its products through e-commerce, retail, and hospitality channels under the Lord Jones and Happy Dance brands in the US. Additionally, Cronos Group Inc. (NASDAQ:CRON) is involved in the cultivation, production, and sales of medical and adult-use cannabis and its related products, and also exports dried cannabis and cannabis oils to several international markets, including Germany, Israel, and Australia.

On November 8, investment advisory Canaccord maintained a Buy rating on Cronos Group Inc. (NASDAQ:CRON) but lowered the firm’s price target on the shares to C$4.75 from C$5. Analyst Matt Bottomley issued the ratings update. 

According to Insider Monkey’s data, 8 hedge funds were long Cronos Group Inc. (NASDAQ:CRON) at the end of Q3 2022, compared to 5 funds in the prior quarter. Traci Lerner’s Chescapmanager LLC is the largest stakeholder of the company, with 8.3 million shares worth $23.4 million. 

6. Aurora Cannabis Inc. (NASDAQ:ACB)

Number of Hedge Fund Holders: 9

Aurora Cannabis Inc. (NASDAQ:ACB) is headquartered in Edmonton, Canada. The company produces, distributes, and sells cannabis and its derivative products globally, with a focus on Canada. Aurora Cannabis Inc. (NASDAQ:ACB) provides medical and consumer cannabis products and is involved in wholesale medical cannabis distribution in the European Union and various international markets, as well as the distribution of hemp-based CBD products in the United States. The company’s portfolio of cannabis products include dried cannabis, oils, capsules, edibles, and extracts. 

On January 4, Aurora Cannabis Inc. (NASDAQ:ACB) announced that it has completed the sale of its Aurora Polaris property for a total of approximately $15 million. Additionally, Aurora Cannabis confirmed that it still expects to achieve adjusted EBITDA profitability in the second fiscal quarter. It has a strong financial position with a net cash balance, boasting approximately $320 million in cash and cash equivalents, including about $63 million in restricted cash. 

Stifel analyst W. Andrew Carter on January 27 maintained a Hold rating on Aurora Cannabis Inc. (NASDAQ:ACB) and lowered the firm’s price target on the shares to C$1.45 from C$1.75. 

According to Insider Monkey’s Q3 data, Aurora Cannabis Inc. (NASDAQ:ACB) was part of 9 hedge fund portfolios, compared to 10 in the last quarter. Jim Simons’ Renaissance Technologies is a significant position holder in the company, with 4.25 million shares worth $5.18 million.

In addition to Jazz Pharmaceuticals plc (NASDAQ:JAZZ), The Scotts Miracle-Gro Company (NYSE:SMG), and Tilray Brands, Inc. (NASDAQ:TLRY), elite investors are piling into Aurora Cannabis Inc. (NASDAQ:ACB) for exposure to the marijuana industry.

Click to continue reading and see 5 Best CBD Stocks To Buy Now

Suggested articles:

Disclosure: None. 11 Best CBD Stocks To Buy Now is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…